Effects of clozapine, olanzapine and haloperidol on nitric oxide production by lipopolysaccharide-activated N9 cells

被引:60
作者
Hou, Yue
Wu, Chun Fu
Yang, Jing Yu
He, Xiang
Bi, Xiu Li
Yu, Liang
Guo, Tao
机构
[1] Shenyang Pharmaceut Univ, Dept Pharmacol, Shenyang 110016, Peoples R China
[2] Gen Hosp Shenyang Mil Reg, Shenyang 110016, Peoples R China
关键词
clozapine; haloperidol; N9; cells; nitric oxide (NO); olanzapine;
D O I
10.1016/j.pnpbp.2006.05.006
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Schizophrenia is a devastating illness of unknown etiology and the basis for its treatment rests in the symptomatic response to antipsychotics. It was found that some of the patients with schizophrenia elicited microglia, activation. The present study used lipopolysaccharide (LPS)-activated mouse microglial cell line N9 as an in vitro model to mimic microglia activation seen in the patients with schizophrenia. The effects of clozapine, olanzapine and haloperidol on the release of nitric oxide (NO) by LPS-stimulated N9 cells were investigated. The results showed that olanzapine significantly inhibited NO release by LPS-stimulated N9 cells. Clozapine and haloperidol did not show significant effects on this model. The present study suggested that the inhibiting effect of olanzapine on the NO release by LPS-stimulated microglial cells might be a new mechanism through which olanzapine exhibits its therapeutic effect in the treatment of schizophrenia. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:1523 / 1528
页数:6
相关论文
共 49 条
[1]  
AKBARIAN S, 1993, ARCH GEN PSYCHIAT, V50, P178
[2]  
ALTAR CA, 1986, BRAIN RES BULL, V16, P517
[3]  
Aravagiri M, 1999, BIOPHARM DRUG DISPOS, V20, P369, DOI 10.1002/1099-081X(199911)20:8<369::AID-BDD200>3.0.CO
[4]  
2-6
[5]   Expression of nNOS and soluble guanylate cyclase in schizophrenic brain [J].
Baba, H ;
Suzuki, T ;
Arai, H ;
Emson, PC .
NEUROREPORT, 2004, 15 (04) :677-680
[6]   TISSUE CONCENTRATIONS OF CLOZAPINE AND ITS METABOLITES IN THE RAT [J].
BALDESSARINI, RJ ;
CENTORRINO, F ;
FLOOD, JG ;
VOLPICELLI, SA ;
HUSTONLYONS, D ;
COHEN, BM .
NEUROPSYCHOPHARMACOLOGY, 1993, 9 (02) :117-124
[7]   Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E [J].
Barger, SW ;
Harmon, AD .
NATURE, 1997, 388 (6645) :878-881
[8]   Evidence for activation of microglia in patients with psychiatric illnesses [J].
Bayer, TA ;
Buslei, R ;
Havas, L ;
Falkai, P .
NEUROSCIENCE LETTERS, 1999, 271 (02) :126-128
[9]   Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial [J].
Beasley, CM ;
Sanger, T ;
Satterlee, W ;
Tollefson, G ;
Tran, P ;
Hamilton, S ;
Green, A ;
Dott, S ;
Pfister, G ;
Roxas, L ;
Small, J ;
Thomas, M ;
Ames, D ;
Schooler, N ;
Baker, R ;
Levine, R ;
Fabre, L ;
Friedel, R ;
Safferman, A ;
Lieberman, J ;
Stahl, S .
PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :159-167
[10]   Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial [J].
Beasley, CM ;
Hamilton, SH ;
Crawford, AM ;
Dellva, MA ;
Tollefson, GD ;
Tran, PV ;
Blin, O ;
Beuzen, JN .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1997, 7 (02) :125-137